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The successful development of the proteasome inhibitor bortezomib as an anticancer drug has improved
survival in patients with multiple myeloma. With the emergence of the newly US Food and Drug
Administration-approved proteasome inhibitor carﬁlzomib, ongoing trials are investigating this com-
pound and other proteasome inhibitors either alone or in combination with other chemotherapy drugs.
However, in solid tumors, the efﬁcacy of proteasome inhibitors has not lived up to expectations. Results
regarding the potential clinical efﬁcacy of bortezomib combined with other agents in the treatment of
solid tumors are eagerly awaited. Recent identiﬁcation of the molecular mechanisms (involving apoptosis
and autophagy) by which bortezomib and cisplatin can overcome chemotherapy resistance and sensitize
tumor cells to anticancer therapy can provide insights into the development of novel therapeutic stra-
tegies for patients with solid malignancies.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
The ubiquitineproteasome system handles 80e90% of intra-
cellular protein catabolism [1]. Proteins to be degraded are initially
ubiquinated and subsequently decomposed into peptides in the
26S proteasome for recycling. Dysregulation of the proteasome
system can lead to several disorders, including malignancies. Bor-
tezomib was the ﬁrst proteasome inhibitor approved by the US
Food and Drug Administration for treatment of multiple myeloma
progressing on prior therapy (in 2003) [2] and relapsed or re-
fractory mantle cell lymphoma (in 2006) (Table 1) [3]. Carﬁlzomib
(the second proteasome inhibitor with higher afﬁnity to protea-
some and lower off-target toxicity) was licensed following accel-
erated approval for treating patients with relapsed and/or
refractory multiple myeloma in 2012 (Table 1) [4,5]. However, the
modest efﬁcacy of bortezomib in solid malignancies necessitates a
study of the mechanisms by which this drug fails in certain cases.
In this review, we focus on the potential usefulness of protea-
some inhibitors in solid malignancies. We ﬁrst summarize clinicalnd Gynecology, Chang Gung
333, Taiwan.
).
bstetrics & Gynecology. Published btrials of newly developed proteasome inhibitors, including carﬁl-
zomib, ixazomib (MLN9708), marizomib, oprozomib, and delan-
zomib (CEP-18770), and then trials involving combinations of
bortezomib and platinum-based agents. The use of proteasome
inhibitors for hematological malignancies is outside the scope of
the present paper and covered in other excellent reviews [4,5].Proteasome inhibitors
Bortezomib
Bortezomib is a boronic acid derivative that speciﬁcally binds to
the b5 catalytic subunit of the 26S proteasome (Table 1) [3]. Bor-
tezomib inhibits proteasome activity, inactivates nuclear factor kB
(NF-kB), induces cancer cell apoptosis through both p53-dependent
and p53-independent mechanisms, and interferes with a number
of different cell cycle signaling pathways [6]. Bortezomib has suc-
cessfully been used as a monotherapy for the treatment of multiple
myeloma and mantle cell lymphoma [2]. In some cases, clinical
response rates were found to be higher when bortezomib was
combined with other drugs, including corticosteroids, alkylating
agents, thalidomide, and/or lenalidomide [7]. Despite the clinical
usefulness of bortezomib for hematological malignancies, ay Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
Table 1
Two FDA-approved proteasome inhibitors.
Bortezomib Carﬁlzomib
Category First generation Second generation
Half-life 10e30 h <30 min
Structural class Dipeptide boronic acid Tetrapeptide epoxyketone
Type of inhibition Reversible, inhibits the chymotryptic-like activity of
20S proteasome
Irreversible, inhibits the chymotryptic-like activity of 20S proteasome
Route of administration Intravenous Intravenous
Clinical indications Approved for multiple myeloma (in 2003) and mantle
cell lymphoma (in 2006)
Approved for relapsed and/or refractory multiple myeloma (in 2012)
FDA¼US Food and Drug Administration.
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been reported [8].
Second-generation proteasome inhibitors: carﬁlzomib, ixazomib,
marizomib, oprozomib, and delanzomib
Second-generation proteasome inhibitors have been developed
with the following goals: (1) to improve treatment efﬁcacy; (2) to
overcome drug resistance; and (3) to reduce adverse effects in
patients treated with bortezomib [5]. Carﬁlzomib is the second US
Food and Drug Administration-approved proteasome inhibitor for
the treatment of recurrentmultiplemyeloma (Table 1) [5]. A total of
four Phase II trials in patients with relapsed and/or refractory
multiple myeloma have shown that hematological and non-
hematological adverse effects related to the use of carﬁlzomib as
monotherapy are tolerable [4]. Ixazomib (MLN9708) and delanzo-
mib (CEP-18770), two orally bioavailable analogs of bortezomib, are
boronate-based molecules that reversibly inhibit the b5 subunit.
Oprozomib (ONX-0912), an analog of carﬁlzomib, is an irreversible
epoxyketone inhibitor with high speciﬁcity for the b5 subunit.
Marizomib is characterized by a b-lactoneeg-lactam backbone that
irreversibly inhibits the catalytic activity of all the three 20S pro-
teasomal subunits (namely, b1, b2, and b5) [9].
Proteasome inhibitors in solid malignancies
Several studies have explored the potential value of bortezomib
in combination with conventional chemotherapeutic agents in
nonhematological malignancies. In general, the therapeutic use-
fulness of bortezomib combined with cytotoxic drugs in solid ma-
lignancies depends on the tumor being treated [9]. The association
of bortezomib, camptothecin, and doxorubicin has been shown to
improve outcomes and reduce toxicity in patients with oral cancer
[10]. Improved survival rates in advanced nonsmall-cell lung cancer
have been reported using sequential administration of docetaxel
and bortezomib [11]. However, the addition of bortezomib to
docetaxel has shown limited therapeutic potential in patients with
metastatic head and neck squamous cell carcinoma [12]. Addi-
tionally, the combination of bortezomib and irinotecan did not
show additional clinical beneﬁts in colorectal cancer [13] or head
and neck squamous cell carcinoma [14]. In general, the potential
clinical utility of bortezomib has been found to be lower in solid
tumors than in hematological malignancies.
Clinical trials of second-generation proteasome inhibitors for
the treatment of solid tumors are summarized in Table 2. A Phase I/
II study evaluating an escalating dose of carﬁlzomib in patients with
advanced solid neoplasms reported that one-ﬁfth of the study
participants achieved stable disease in Phase II cohorts [15]. The
addition of other cytotoxic agents to augment proteasome inhibi-
tion resulted in a fewmanageable side effects. Notably, the absence
of peripheral neuropathy can favor the use of carﬁlzomib incombination therapies [15]. Similarly, the efﬁcacy of marizomib
combined with vorinostat in patients with melanoma is encour-
aging [16]. Fatigue, lymphopenia, and anemia have been observed
in a Phase I/II study of patients with solid tumors treated with
carﬁlzomib monotherapy [6]. In addition, skin rash has been
observed in >50% of patients with solid tumors treated with
delanzomib [17]. The optimal dose for avoiding this adverse event
remains to be determined.
Special consideration: bortezomib combined with platinum-based
chemotherapy and/or radiation in solid tumors
A combination regimen consisting of bortezomib and platinum-
based agents has shown promising results in a Phase I study of
ovarian cancer [18,19]. Moreover, the use of bortezomib in con-
current chemoradiation regimens is well tolerated in patients with
head and neck malignancies [20]. Phase II clinical trials have been
conducted to further explore the efﬁcacy of these combinations
(Table 3). A survival beneﬁt has been reported in patients with
nonsmall-cell lung carcinomas [21e23]. However, a poor clinical
response has been observed in malignant pleural mesothelioma
[24], metastatic esophageal cancer [25], and metastatic melanoma
[26]. The addition of bortezomib to liposomal doxorubicin allowed
the achievement of a partial response in 24% of platinum-sensitive
patients with ovarian cancer, although no responsewas observed in
chemoresistant patients [27]. Whether tumors are sensitive or
resistant to platinum seemingly affects the efﬁcacy of bortezomib
combined with other chemotherapy agents, ultimately requiring
further scrutiny. Notably, severe adverse effects have been
observed with the combined treatment. Grade 3/4 hematological
adverse effects included thrombocytopenia (10e63%) and neu-
tropenia (10e71%) [21e27]. The most common nonhematological
toxicities were peripheral neuropathy, diarrhea, and fatigue.
Apoptosis and autophagy elicited by bortezomib combined
with cisplatin
Phosphorylation of signal transducer and activator of tran-
scription 1 (STAT1) reduces bortezomib-mediated apoptosis in
cancer cells. To investigate the signaling pathways elicited by bor-
tezomib in solid malignancies, a panel of 11 reporter assays has
been tested in ovarian cancer cells. Although inhibition of the
transcription factor NF-kB is believed to be a keymechanism for the
antimyeloma effect of bortezomib [28], the NF-kB reporter activity
was not found to be affected in ovarian cancer cells [29]. In contrast,
bortezomib stimulated STAT1 tyrosine phosphorylation [29]. Dys-
regulation of STAT1 has been reported in a number of different
malignancies [30], but its role remains controversial because it can
act either as a proapoptotic [31] or as a prosurvival factor [32].
STAT1 is signiﬁcantly overexpressed in drug-resistant cancer cells
compared with that in drug-sensitive cancer cells or normal cells
Table 3
Phase II trials of bortezomib combined with platinum-based agents in patients with solid tumors.a
Trial No. of patients Description of the study Clinical outcome
Phase II study
NCT00052338/
NCT00075751
Southwest Oncology Group
study (S0339) [21]
114 Advanced NSCLC
Gemcitabine 1000 mg/m2, Days 1 and 8; carboplatin AUC
5.0, Day 1; and bortezomib 1.0 mg/m2, Days 1, 4, 8, and 11
Notable survival beneﬁts; median OS: 11 mo; 1-y survival
rate: 47%; response rate: 23%; disease control rate (response
plus stable disease): 68%
Phase I/II study [22] 16 Advanced NSCLC
Carboplatin AUC 6 and bevacizumab (15 mg/kg)
q 3 wk using a standard Phase I design. Bortezomib
doses were 1.3 mg/m2, 1.6 mg/m2, and 1.8 mg/m2
weekly on Days 1 and 8 of q 3-wk cycle
Response rate and OS in the entire study cohort were 37.5%
and 9.9 mo, respectively. The response rate and OS for the
nine patients in Phase II portion were 44% and 10.9 mo,
respectively
Phase I/II study
NCCTG-N0321 [23]
27 NSCLC
Bortezomib, paclitaxel, and carboplatin concomitantly
with thoracic radiation (60 Gy/30 daily fractions)
Median OS: 25.0 mo
NCT00458913
Phase II study
European Organisation for
Research and Treatment
of Cancer 08052 [24]
82 Malignant pleural mesothelioma
Cisplatin 75 mg/m2 on Day 1 and bortezomib
1.3 mg/m2 on Days 1, 4, 8, and 11 every 3 wk
OS: 13.5 mo; the study did not reach a 50% progression-free
survival rate at 18 wk
Phase II study
NCCTG-N044B [25]
35 Metastatic esophageal, gastric, and gastroesophageal
cancer
Bortezomib 1.2 mg/m2 on Days 1, 4, and 8; paclitaxel
175 mg/m2 on Day 2; and carboplatin with AUC of
6 on Day 2
RR: 23%, OS: 8.9 mo
Two-stage Phase II
study [27]
58 Relapsed ovarian cancer, previously treated with
platinum (100%) and taxane (95%), received bortezomib
1.3 mg/m2 intravenous (Days 1, 4, 8, and 11), and
lipodox 30 mg/m2 intravenous (Day 1), every 3 wk
Platinum-sensitive group; 24% PR
Platinum-resistant group; 0%
Two-stage Phase II
study [26]
17 Metastatic melanoma, receiving at least one prior
cycle of chemotherapy
Bortezomib 1.3 mg/m2 given intravenously on Days
1, 4, and 8, paclitaxel 175 mg/m2 and carboplatin AUC
6 on Day 2 of a 21-d cycle
Median OS: 7.0 mo
AE¼ adverse events; AUC¼ area under the curve; NCCTG¼North Central Cancer Treatment Group; NSCLC¼ nonsmall-cell lung carcinoma; OS¼ overall survival; PR¼ partial
response; RR ¼ response rate.
a The review was updated on October 2015.
Table 2
Completed or ongoing clinical trials of second-generation proteasome inhibitors in patients with solid tumors.a
Trial Phase Drug(s) No. of patients Current status Response/side effect
NCT02512926 I Carﬁlzomib plus (cyclophosphamide,
etoposide)
50 Recruiting NA
NCT02257476 I Carﬁlzomib 30 Recruiting NA
NCT01949545 I Carﬁlzomib 40 Recruiting NA
NCT01941316 I/II Carﬁlzomib plus irinotecan 112 (small cell lung cancer) Recruiting NA
NCT00667082 [16] I Marizomib plus vorinostat 22 (lung cancer, pancreatic cancer,
and melanoma)
Completed Stable disease rate: 61%
Nausea and vomiting related to marizomib
NCT00629473 I Marizomib 86 Completed NA
NCT00396864 I Marizomib 51 (solid tumors and lymphoma) Completed NA
NCT00572637 [17] I Delanzomib (CEP-18770) 30 (evaluable, solid tumors) Completed No objective responses
70% of the study patients developed
Grade 3 skin rash at a dose of 1.5 mg/m2
NCT00830869 I Ixazomib (MLN9708) 116 Completed NA
NCT01912222 I Ixazomib 48 Completed NA
NCT02042989 I Ixazomib plus vorinostat 56 Recruiting NA
NCT02384746 I Ixazomib plus fulvestrant 18 (breast cancer) Recruiting NA
NCT02420847 I Ixazomib plus (gemcitabine, doxorubicin) 57 (bladder cancer) Recruiting NA
NCT01129349 I Oprozomib 44 Completed NA
NA ¼ not applicable.
a The review was updated in October 2015.
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with reduced sensitivity to bortezomib in ovarian cancer cells [29].
Either knockdown of heat shock factor-1 (HSF1) or pharmacological
suppression of Janus kinase (JAK) blocked bortezomib-stimulated
STAT1 phosphorylation (Figure 1). These ﬁndings are consistent
with a report showing that an HSF1 inhibitor enhances the anti-
cancer effects of bortezomib in myeloma cells [34]. The results of
animal studies also support the notion that the addition of a JAKinhibitor, AG490, to bortezomib treatment can exert synergistic
cytotoxic effects on ovarian cancer cells via suppression of STAT1
phosphorylation [29]. Bortezomib has been also used to overcome
cisplatin resistance [35,36]. Notably, bortezomib-induced STAT1
phosphorylation seems to be inhibited by cotreatment with
cisplatin [29], potentially explaining the synergistic antitumoral
effect of the combination of cisplatin and bortezomib [37]. Taken
together, a combinatory treatment with bortezomib, cisplatin, a JAK
Figure 1. Combination treatment with bortezomib, cisplatin, and a JAK inhibitor
provides a chemotherapeutic strategy for treating solid malignancies. Bortezomib in-
creases HSF1 and transcriptionally upregulates HSP70, which subsequently induces
STAT1 phosphorylation. Bortezomib can also induce STAT1 phosphorylation through
the JAK signaling pathway. Notably, cisplatin and the JAK inhibitor signiﬁcantly sup-
press STAT1 phosphorylation and enhance cytotoxicity in bortezomib-treated cells.
These results suggest the possibility of overcoming bortezomib resistance in cancer
cells through the addition of cisplatin and/or JAK inhibitors. Akt ¼ serine-threonine
protein kinase; Bcl-2 ¼ B-cell lymphoma 2; Bcl-XL ¼ B-cell lymphoma-extra large;
Bid ¼ BH3 interacting-domain death agonist; HSF ¼ heat shock factor; JAK ¼ Janus
kinase; P-Bad ¼ phospho-Bcl2-associated agonist death promoter; P-
STAT1 ¼ phosphorylation of signal transducer and activator of transcription 1;
STAT1 ¼ signal transducer and activator of transcription 1.
Figure 3. Strategies of integrating proteasome inhibitors and platinum. Proteasome
inhibitors as monotherapy did not show major efﬁcacy in treating solid cancers;
however, bortezomib in combination with other drugs appears to be a promising
strategy in this scenario. STAT1 ¼ signal transducer and activator of transcription 1.
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strategy for solid malignancies (Figure 1).
Bortezomib enhances cancer cell death by inhibiting autophagy
through increased phosphorylation of extracellular signal-regulated
kinases (ERK)
The role of autophagy in cancer cells is complex and context
speciﬁc [38]. Upon exposure to chemotherapeutic drugs, cancerFigure 2. Bortezomib enhances cancer cell death by inhibiting the catabolic process of
autophagy through increased phosphorylation of ERK. Cancer cells can use autophagy
as a form of self-rescue upon treatment with cisplatin. Increased levels of CTSB are
required to complete the autophagy process. Treatment with bortezomib induces
phosphorylation of ERK, which decreases CTSB levels and blocks autophagy. When
cancer cells are treated with bortezomib and cisplatin-based chemotherapy, self-
rescuing autophagy is suppressed in cancer cells, ultimately resulting in enhanced
antitumor efﬁcacy. CTSB ¼ cathepsin B; ERK = extracellular signal-regulated kinases.cells can undergo autophagy as a self-rescue process [39]. More-
over, autophagy in cancer cells may be a cause of drug resistance
[40]. The process of autophagy begins with the formation of auto-
phagosomes that engulf cytoplasmic material and organelles. Light
chain 3-II plays a critical role in the elongation of the autophago-
some double membrane [41]. The mature autophagosome subse-
quently fuses with a lysosome to form an autolysosome (where the
autolysosomal components are degraded by lysosomal catalytic
enzymes, including cathepsin B) (Figure 2). The autolysosomal
components include p62 [also known as sequestosome 1 (SQTM1)],
whose degradation indicates that the autophagy process has been
completed [42].
Bortezomib has been shown to stimulate autophagy in some
[43] but not all studies [44]. Autophagy proteins have recently been
shown to regulate the functions of ERK [45], whereas ERK activa-
tion is able to induce autophagy [46]. In contrast, sustained acti-
vation of ERK inhibits the maturation step of the autophagy process
[47]. Recent evidence suggests that bortezomib can block the
autophagic ﬂux via the phospho-ERK-mediated inhibition of
cathepsin B [48] (Figure 2). The discovery that bortezomib may
block chemotherapy-induced autophagy can be clinically impor-
tant because the commonly used chemotherapeutic agent cisplatin
is known to stimulate autophagy of ovarian cancer cells [49].
Accordingly, the combination of bortezomib and cisplatin has been
found to exert synergistic antitumor effects in a xenograft mouse
model of ovarian cancer. Immunohistochemical studies of xeno-
grafted tumor tissues further conﬁrmed that treatment with bor-
tezomib stimulated ERK phosphorylation and inhibited cathepsin
B, resulting in the accumulation of p62/sequestosome 1 (an indi-
cator of autophagy blockade) [48].
Conclusions
Bortezomib may exert antitumor effects by regulating two
critical cellular processes, i.e., apoptosis [29] and autophagy [48].
From one point of view, bortezomib as a single agent does not
appear to be very effective in killing ovarian cancer cells, because
STAT1 is activated through phosphorylation (which suppresses
apoptosis). The addition of cisplatin, a JAK inhibitor, or an HSF1
inhibitor can block bortezomib-stimulated STAT1 activation
(Figure 1). In contrast, chemotherapeutic agents frequently stimu-
late autophagy in cancer cells, which has evolved as a self-rescuing
mechanism in cancer cells. The addition of bortezomib can block
A. Chao, T.-H. Wang / Taiwanese Journal of Obstetrics & Gynecology 55 (2016) 3e8 7the autophagic ﬂux and may ultimately enhance the cytotoxic ef-
fects of chemotherapy (Figure 2). Although proteasome inhibitors
as monotherapy do not seem to have major efﬁcacy in solid ma-
lignancies, their combination with other therapeutic classes holds
signiﬁcant promise in this scenario (Figure 3).
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